Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re: ADDERALL XR ANTITRUST
-
June 09, 2014
2nd Circ. Affirms Dismissal Of Adderall Pay-For-Delay Suit
The Second Circuit on Monday found that Shire LLC didn't block generic competition for its attention-deficit-hyperactivity drug Adderall XR, saying a lower court was correct to dismiss a consolidated class action because Shire's patent licensing agreements didn't raise an antitrust issue.
-
March 17, 2014
Wholesalers Ask 2nd Circ. To Toss Shire Pay-For-Delay Win
Attorneys for drug wholesalers claiming Shire LLC smothered generic competition for attention-deficit-hyperactivity drug Adderall XR told a Second Circuit panel Monday that a district court wrongly concluded that Shire's alleged breaches of patent licensing agreements aren't actionable under federal antitrust law.
-
October 04, 2013
Adderall Antitrust Suit Should Stay Buried, 2nd Circ. Hears
Shire LLC pushed back Friday against two drug wholesalers' bid to revive a consolidated class action alleging Shire stifled generic-drug competition for its blockbuster attention deficit hyperactivity disorder treatment Adderall XR, saying the lower court correctly ruled that Shire's patent licensing agreements didn't raise an antitrust issue.